Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patients with chronic lymphocytic leukemia or multiple myeloma whose disease has been controlled with chemotherapy: rituximab anti-CD20 monoclonal antibody or interferon alpha 2-b as maintenance therapy

Next Previous
X
Search
Trial Profile

Patients with chronic lymphocytic leukemia or multiple myeloma whose disease has been controlled with chemotherapy: rituximab anti-CD20 monoclonal antibody or interferon alpha 2-b as maintenance therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b; Rituximab
  • Indications Chronic lymphocytic leukaemia; Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Aug 2015 Biomarkers information updated
    • 10 May 2011 Planned end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 10 May 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top